Trevi Therapeutics
TRVI
17 hedge funds and large institutions have $28.1M invested in Trevi Therapeutics in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
3.33% less ownership
Funds ownership: 65.94% → 62.61% (-3.3%)
11% less funds holding
Funds holding: 19 → 17 (-2)
21% less capital invested
Capital invested by funds: $35.6M → $28.1M (-$7.51M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$56.3K |
| 2 |
BlackRock
New York
|
+$26.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.64K |
| 4 |
First Manhattan
New York
|
+$3.6K |
| 5 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
+$2.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.57M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$169K |
| 3 |
Renaissance Technologies
New York
|
-$65.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$29K |
| 5 |
Morgan Stanley
New York
|
-$3K |
TRVI Hedge Fund Activity: Q2 2021 in Review
17 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2021, worth a combined $28.1M — down 21% from $35.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TRVI and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Alberta Investment Management Corp (AIMCo), opening a new position worth an estimated $56.3K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.57M sold.
- 17 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2021, down from 19 in Q1 2021.
- Funds reported $28.1M of Trevi Therapeutics stock for Q2 2021, down 21% quarter-over-quarter.
- 2 funds opened new Trevi Therapeutics positions in Q2 2021 and 4 closed out, a net change of -2 holders.
- The largest Trevi Therapeutics buyer in Q2 2021 was Alberta Investment Management Corp (AIMCo), an estimated $56.3K added.
- The largest Trevi Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $1.57M sold.
Based on aggregated 13F filings for Q2 2021.